ValiRx CEO says drug sell-off will raise cash and free-up resources

Dr Satu Vainikki, the Chief Executive of ValiRx (LON:VAL), says selling their Finnish subsidiary and consequently its TRAC technology represents an ”exciting commercialisation of a part of our portfolio”.

Vainikki says Valirx will still retain the license to use the technology in their development of therapeutic candidates.